Singapore markets close in 3 hours 40 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.03+0.06 (+1.01%)
At close: 04:00PM EST
6.00 -0.03 (-0.50%)
After hours: 07:59PM EST

Ocugen, Inc.

263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
484 328 4701

Full-time employees15

Key executives

NameTitlePayExercisedYear born
Dr. Shankar Musunuri M.B.A., Ph.D., MBACo-Founder, Chairman & CEO780.67kN/A1964
Dr. Uday B. Kompella Ph.D.Co-founder & Independent Director44.77kN/A1967
Mr. Sanjay S. Subramanian M.B.A.Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec.511.15kN/A1976
Mr. Ken InchaustiHead of Investor Relations & CommunicationsN/AN/AN/A
Ms. Zara GaudiosoHead of HRN/AN/AN/A
Dr. Vijay TammaraSr. VP of Regulatory & QualityN/AN/A1960
Dr. Arun Upadhyay Ph.D.Head of Research, Devel. & DiscoveryN/AN/AN/A
Dr. Bruce D. Forrest B.S., M.B.A., M.D.Acting Chief Medical Officer & Vaccine Scientific Advisory Board MemberN/AN/A1963
Mr. J. P. GabrielSr. VP of Manufacturing & Supply ChainN/AN/AN/A
Mr. Michael ShineSr. VP of CommercialN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Corporate governance

Ocugen, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.